Third, it has been reported that the expression of the NMT2 gene is significantly decreased or even completely lost in certain hematological cancer types; hence, the development of a selective NMT1 inhibitor is of interest to the biotech industry [20]. This evidence concerns the gene NMT1 and hematopoietic and lymphoid cell neoplasm.